China Health Group Inc. (8225) AI Stock Analysis

• Market Cap: HK$132.38M
• Dividend Yield: N/A
• Average Volume (3M): 266.67K
• Price to Earnings (P/E): 8.6
• Beta (1Y): 0.95
• Revenue Growth: 19.97%
• EPS Growth: 76.51%
• Country: HK
• Employees: 42
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 995,351,700
• 10 Day Avg. Volume: 154,000
• 30 Day Avg. Volume: 266,666
• PEG Ratio: 0.17
• Price to Book (P/B): 2.64
• Price to Sales (P/S): 7.03
• P/FCF Ratio: 21.81
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: HK$0.14 ▲(2.14% Upside)
• Action: Upgraded Date: 12/30/25
• Date: Action: Upgraded 12/30/25

The score is primarily held back by continued large losses and high earnings volatility despite the 2024 revenue rebound and improved cash flow. Technicals are also weak with the stock trading below key moving averages and negative MACD. A debt-light balance sheet provides some stability, but valuation remains difficult to support given negative earnings and no dividend data.

Positive Factors

Revenue Growth

The strong revenue rebound in 2024 indicates potential recovery and growth, suggesting improved market conditions and business execution.

Cash Flow Improvement

Improved cash flow in 2024 enhances financial flexibility and indicates better cash management, which is crucial for sustaining operations.

Low Debt Levels

A low-debt balance sheet reduces solvency risk and provides financial stability, allowing the company to focus on operational improvements.

Negative Factors

High Earnings Volatility

Persistent earnings volatility and losses indicate execution risks and challenge long-term profitability, impacting investor confidence.

Negative Profitability

Ongoing losses and negative margins highlight structural profitability issues, which could hinder future growth and investment potential.

Equity Erosion

Declining equity due to cumulative losses weakens the financial foundation, posing risks to long-term stability and shareholder value.

China Health Group Inc. Business Overview & Revenue Model

Company Description

China Health Group Inc., an investment holding company, provides clinical research services to pharmaceutical and biotechnology companies in the People's Republic of China. The company offers contracted clinical research services; contracted pharmaceutical development services; post launch market research, medical, and medical market services; medical science liaisons; and other medical services. It also provides hospital management, medical tourism, and specialized hospital services, as well as Venturepharma cloud; and sells drug technologies. The company was formerly known as Venturepharm Laboratories Limited and changed its name to China Health Group Inc. in January 2015. China Health Group Inc. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.

How the Company Makes Money

China Health Group Inc. generates revenue through several key streams. The company earns income from providing medical services, which may include hospital operations, outpatient services, and specialty care. Additionally, it manages healthcare facilities, offering operational and administrative expertise to improve efficiency and patient care. Another significant revenue stream is the development and distribution of healthcare products, which can include pharmaceuticals, medical devices, and health supplements. Partnerships with other healthcare organizations and governmental bodies may also contribute to its revenue, as they can enhance service delivery and expand market reach. These various activities collectively support the company's earnings and growth strategy.

China Health Group Inc. Financial Statement Overview

Summary

Mixed fundamentals: strong 2024 revenue rebound and improved cash flow (positive operating and free cash flow), supported by a low-debt balance sheet. However, the company remains materially loss-making with high earnings volatility since 2021, and equity has been trending down due to cumulative losses.

Income Statement

Revenue rebounded strongly in 2024 (+212% YoY) after a weak 2022–2023, but profitability remains a major issue. The business is still loss-making in 2024 (net margin ~-55% and negative operating margin), even though losses improved materially versus 2023’s very deep red margins. Gross margin held relatively steady around ~38% in 2023–2024, suggesting the main drag is operating cost structure rather than product-level economics; however, the sharp swing from strong profits in 2019–2021 to sustained losses in 2022–2024 highlights elevated earnings volatility and execution risk.

Balance Sheet

The balance sheet is conservatively financed with essentially no debt in recent years (debt-to-equity at 0.0 in 2022–2024), which reduces solvency risk and gives flexibility. That said, equity has trended down from 2021 to 2024, consistent with cumulative losses, and returns on equity are negative in 2022–2024, indicating shareholder capital is not currently earning a positive return. Overall leverage is low, but the key risk is continued erosion of the equity base if losses persist.

Cash Flow

Cash generation improved meaningfully in 2024 with positive operating cash flow (10.3M) and positive free cash flow (8.5M), a sharp turnaround from negative free cash flow in 2022–2023. Cash flow has also been inconsistent historically (including negative operating cash flow in 2019 and 2021), but the latest year shows better cash discipline. A key watch item is that 2024 operating cash flow covered only about one-third of the net loss, meaning cash generation is improving but the underlying profitability gap hasn’t fully closed.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	29.78M	26.45M	21.43M	13.09M	83.60M	83.06M
Gross Profit	12.03M	10.07M	8.21M	5.74M	63.86M	66.96M
EBITDA	-12.52M	-14.24M	-57.98M	-15.66M	42.74M	55.32M
Net Income	-13.17M	-14.52M	-58.01M	-15.84M	36.33M	60.65M
Balance Sheet
Total Assets	110.02M	100.96M	119.35M	178.63M	198.11M	159.90M
Cash, Cash Equivalents and Short-Term Investments	25.43M	15.89M	7.30M	12.07M	17.02M	28.35M
Total Debt	0.00	0.00	0.00	0.00	0.00	1.50M
Total Liabilities	31.60M	31.24M	35.17M	36.74M	42.54M	41.22M
Stockholders Equity	79.05M	70.35M	84.82M	142.32M	155.57M	118.67M
Cash Flow
Free Cash Flow	15.18M	8.52M	-4.88M	-5.16M	-10.28M	19.11M
Operating Cash Flow	16.94M	10.28M	1.12M	-5.16M	-10.28M	19.11M
Investing Cash Flow	-65.00K	-230.00K	-1.04M	-2.15M	6.96M	-11.97M
Financing Cash Flow	0.00	0.00	0.00	0.00	-1.51M	593.00K

China Health Group Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8225, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.14, below the 50-day MA of 0.14, and below the 200-day MA of 0.16, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 36.31 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8225.

China Health Group Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2293	75 Outperform	HK$189.16M	5.31	6.92%	8.00%	-21.50%	-43.25%
0928	58 Neutral	HK$181.34M	7.17	-16.81%	―	-58.65%	-370.13%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
8225	48 Neutral	HK$132.38M	8.60	-16.17%	―	19.97%	76.51%
8622	48 Neutral	HK$175.26M	-38.07	-8.95%	―	2.54%	33.33%
2159	47 Neutral	HK$540.40M	-6.27	-35.99%	―	-5.38%	63.93%